Condition: Breast Cancer · Solid Tumor · Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
In this study, the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), recommended phase II dose (RP2D), the preliminary efficacy, pharmacokinetic characteristics, and immunogenicity of BL-B01D1 will be investigated in patients with unresectable locally advanced or metastatic breast cancer and other solid tumors.
This description comes directly from the study's public registry record.
Sa Xiao, PHD · +86-15013238943 · xiaosa@baili-pharm.com
Always discuss trial participation with your own doctor first.
| Guangdong Provincial People's Hospital | Guangzhou, Guangdong, China | Recruiting |
| Fudan University ShangHai Cancer Center | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05470348